AstraZeneca: FDA priority review for Tagrisso
(CercleFinance.com) - AstraZeneca announces that the FDA has accepted - for priority review - its supplemental new drug application (sNDA) for Tagrisso (osimertinib), in combination with chemotherapy, as a potential treatment for adults with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFRm) mutation.
The FDA's decision is expected in Q1 2024.
AstraZeneca said that trial results show that Tagrisso offers patients an additional nine months of progression-free survival when combined with chemotherapy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The FDA's decision is expected in Q1 2024.
AstraZeneca said that trial results show that Tagrisso offers patients an additional nine months of progression-free survival when combined with chemotherapy.
Copyright (c) 2023 CercleFinance.com. All rights reserved.